


The WIN Consortium in Precision Oncology

www.winconsortium.org



WIN was formed on the premise that Consortium members can accomplish together what no single institution or group of patients can do alone.

WIN was founded in France as a non-profit by **Dr. John Mendelsohn**, Past President MD Anderson Cancer Center, Houston, Chairman of WIN until his death and **Prof. Thomas Tursz**, General Director Gustave Roussy, France.

BOLD MISSION Significantly improve survival of cancer patients across the world through international collaboration.

STRATEGY: Perform proof-of-concept cancer clinical trials designed to explore novel strategies and tools to increase efficacy of Precision Oncology and improve early diagnosis

Publications

WINTHER trial results

J. Rodon et al., Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. *Nature Medicine* volume 25, pages 751-758 (2019)

Simplified interventional mapping system (SIMS)

Lazar V, et al. Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors. *Therapeutic Advances in Medical Oncology*. 2024;16

Solomon B, et al. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. *Cancer Med*. (2022) ;00:1-11

Digital Display Precision Predictor (DDPP)

Lazar, V., et al., Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. (2021) *npj Precis. Onc.* 5, 33.

Lazar, V., et al., Transcriptomics in tumor and normal lung tissues identify patients with early stage NSCLC with high risk of post-surgery recurrence who may benefit from adjuvant therapies *JCO Precision Oncology* no. 6 (2022) e2200072. Published online

Lazar, V., et al., Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung. *Therapeutic Advances in Medical Oncology* (2022), Vol. 14: 1-15

Lazar, V., et al., A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. *Ther Adv Med Oncol* (2023), Vol. 15: 1-15

WIN History

John Mendelsohn, Past President MD Anderson Cancer Center, Houston, USA

Chair, WIN 2010 - 2018



Thomas Tursz, Past General Director Gustave Roussy, Villejuif, France

Vice-Chair, WIN 2010 - 2012, 2016 - 2018



Alexander Eggermont, Past General Director Gustave Roussy, Villejuif, France

Vice-Chair, WIN 2012 - 2016



Josep Tabernero, Head Vall d'Hebron Institute of Oncology, Barcelona, Spain

Vice-Chair, WIN 2018 - 2023



Richard L. Schilsky, Past President, former Executive VP and Chief Medical Officer, ASCO, USA

Chair, WIN 2018 - 2023



Wafik El-Deiry, Director, Legorreta Cancer Center, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, USA

Chair, WIN 2024 -



WIN Executive Committee



Prof. Wafik S. El-Deiry
Chair, WIN Consortium
Director, Legorreta Cancer
Center, Brown University (USA)



Dr. Richard L. Schilsky
Chair Emeritus, WIN Consortium
Professor Emeritus, University of
Chicago
Past President & Chief Medical
Officer, American Society of Clinical
Oncology (ASCO) (USA)



Dr. Razelle Kurzrock
Chief Medical Officer, WIN Consortium
Prof. of Medicine, Associate Director,
Clinical Research, MCW Cancer Center
and Linda T. & John A. Mellowes
Chair of Precision Oncology (USA)



Prof. Apostolia M. Tsimberidou
Vice-Chair, WIN Consortium
Professor of Medicine in the
Department of Investigational Cancer
Therapeutics and a Katherine Russell
Dixie Distinguished Endowed
Professor at The University of Texas,
MD Anderson Cancer Center (USA)



Dr. Sewanti Limaye
Vice-Chair, WIN Consortium
Director Medical & Precision
Oncology, Director Clinical and
Translational Oncology Research,
Sir HN Reliance Foundation
Hospital and Research Centre
(India)



Prof. Marina Sekacheva
Chair, Membership Committee,
WIN Consortium
Director of Institute for
Personalized Oncology, I.M
Sechenov First Medical State
University,
(Russian Federation)



Dr. Jacques Raynaud,
Senior Advisor, WIN
Consortium



Catherine Bresson
Director, Operational
Team, WIN Consortium

WIN 33 Members across the Globe

Academic Institutions in Americas



Academic Institutions in Asia-Pacific



Academic Institutions in Europe



Small & Medium Enterprises




Non-Profit Organizations



World-class academic medical centers SME (3), research and patient advocate organizations (4).

33 members in
19 countries and 5 continents
Access to > 5,000,000 patients
www.winconsortium.org



#	Institution	#	Institution	#	Institution
1	Avera Cancer Institute, USA	13	Vall d'Hebron Institute of Oncology (VHIIO), Spain	25	I.M. Sechenov First Moscow State Medical University, Russia
2	American Cancer Society, USA	14	Catalan Institute of Oncology (ICO), Spain	26	National Center for Cancer Care & Research Hamed Medical Corporation, Qatar
3	Atrium Health Wake Forest Baptist Comprehensive Cancer Center, USA	15	Cure 51, France	27	Burjeel Medical City, UAE
4	Rutgers Cancer Institute, USA	16	Centre Léon Bérard, France	28	Tata Memorial Centre, India
5	Cancer is An A* LLC, USA	17	Luxembourg Institute of Health, Luxembourg	29	Sir H.N. Reliance Foundation Hospital and Research Centre, India
6	Chaim Resource Organization, USA	18	Centre Hospitalier de Luxembourg, Luxembourg	30	Vyas Cancer Research Pvt (VCR Park), China
7	Segal Cancer Centre, Jewish General Hospital, McGill University, Canada	19	Novocure, Switzerland	31	Fudan University Shanghai Cancer Center, China
8	Legorreta Cancer Center at Brown University, USA	20	The University of Medicine and Pharmacy Iuliu Haiegeanu, Romania	32	Institute of Science Tokyo Hospital, Japan
9	TargetCancer Foundation, USA	21	Medicana Health Group, Demiray Precision Oncology Center, Turkey	33	The Kinghorn Cancer Centre, Australia
10	The Jackson Laboratory, USA	22	Ben-Gurion University of the Negev, Israel		
11	Barmes Cancer Hospital, Brazil	23	Sheba Medical Center, Israel		
12	INCLIVA, Spain	24	King Hussein Cancer Center, Jordan		


WIN Value Proposition

- ❑ Access to:
 - Global thought leaders in Precision Oncology
 - Platform of leading cancer centers across the world → rapid accrual/diversity of population
- ❑ Expertise in genomics and transcriptomics
- ❑ Experience and success with:
 - Complex biomarker-directed clinical trials (WINTHER trial)
 - Obtaining high quality tissues and bloods for comprehensive omics
 - Managing international multi-site trials
 - International Molecular Tumor Board
- ❑ Ability to partner with companies and philanthropic organizations or individuals to perform Precision Oncology studies to:
 - Better identify treatment options for patients including optimal dosing of novel combination therapies
 - Understand mechanisms of resistance to cancer therapy
 - Improve patients' treatment follow-up and early diagnosis non-invasively
 - Accelerate drug development through better patient selection

Lazar V, et al. Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors. *Therapeutic Advances in Medical Oncology*. 2024;16

El-Deiry, et al., Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing Next-Generation Precision Oncology to Patients. *Oncotarget*. 2025; 16:140-162

A Hernando-Calvo, et al., Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment *Oncotarget*. 2025; 16:456-466.
O. Landau, et al. OncoAID: An Open Access Targeted Anti-Cancer Database Front. Pharmacol., 13 August 2025 Sec. Pharmacology of Anti-Cancer Drugs Volume 16 - 2025



14th WIN Symposium, held in cooperation with APM on October 3-4, 2025, in Philadelphia, USA, and co-chaired by Prof. W. El-Deiry and Dr. R. Kurzrock, marked another highlight in a remarkable series of symposia. The conference featured a special session with Nobel Laureate Dr. William G. Kaelin Jr. (Harvard Medical School, Dana-Farber Cancer Institute).

WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East

A Vision for WIN's Future

- ☐ Expand the WIN membership with additional:
 - World-class cancer centers in US and across the globe
 - Diagnostics, AI, pharma companies, patient-advocacy organizations, non-profits
- ☐ Leveraging WIN's platform for global academic members to:
 - Partner with companies for compelling Precision Oncology and Early Diagnosis studies across the globe
 - Build upon transcriptomics' experience acquired in international clinical trials like WINHER and others that have so much potential → incorporating Functional Precision Medicine assays and novel modalities
 - Accelerate trial results delivery and simplify management of multi-site international trials
- ☐ Leverage WIN IP (algorithm for patient's treatment matching and patient stratification)
- ☐ New initiatives such as international Molecular Tumor Board and International Precision Oncology Fellowship
- ☐ Involve WIN's exceptional SAB - Innovation and Collaboration globally to ensure continued success
- ☐ Strengthen relationships with professional societies (ACS, ASCO, AACI, AACR, etc.)

Membership Benefits

- ☐ Representation at international General Assembly (right to vote on all decisions)
- ☐ Access to governance positions (2-year mandates)
- ☐ Ability to participate in WIN Committees and International Molecular Tumor Board for faculty
- ☐ Ability to participate in WIN-managed studies
- ☐ Ability to propose studies to be performed in WIN member institutions, but no obligation
- ☐ Each project is subject to contract negotiated in good faith. Usual IP rules apply
- ☐ Each project needs a separate funding mechanism. All participants in studies required to participate in the effort
- ☐ Visibility on website, symposia


Annual Membership Dues

Academics: From 5,000 to 50,000 € depending on research budget

Industries: Pharma 250,000 € ; Technology partners 100,000 €

Committees

- ❑ International Molecular Tumor Board with Precision Oncology experts from 19 sites and 13 countries. Discussing complex clinical cases with a focus on tailored combinations. Cases are being published.



#	Institution	#	Institution
1	Avera Cancer Institute, USA	11	Centre Hospitalier de Luxembourg, Luxembourg
2	Rutgers Cancer Institute, USA	12	The Oncology Institute Ion Chiricuta (IOCN), Romania
3	Chaim Medical Resource Organization, USA	13	Sheba Medical Center, Israel
4	Segal Cancer Centre, Jewish General Hospital, McGill University, Canada	14	King Hussein Cancer Center, Jordan
5	Legorreta Cancer Center at Brown University, USA	15	Burjeel Medical City, UAE
6	The Jackson Laboratory, USA	16	Sir H.N. Reliance Foundation Hospital and Research Centre, India
7	Vall d'Hebron Institute of Oncology (VHIO), Spain	17	Fudan University Shanghai Cancer Center, China
8	Catalan Institute of Oncology (ICO), Spain	18	Institute of Science Tokyo Hospital, Japan
9	Worldwide Innovative Network (WIN) Association - WIN Consortium, France	19	The Kinghorn Cancer Centre, Australia
10	Centre Léon Berard, France		

- ❑ Membership Committee
- ❑ Symposium Committee
- ❑ Training and Publication Committee
- ❑ Data Science Committee
- ❑ Rare cancers Committee
- ❑ Disease Committees: GI, GU, Thoracic, CNS, Gynaecology, Breast
- ❑ Biomarkers Committee
- ❑ Precision Radiation Oncology / Imaging Committee
- ❑ Novel Agents Committee
- ❑ Regulatory Issues in Precision Oncology Committee
- ❑ Novel tissue agnostic biomarkers Committee
- ❑ Living Guidelines Committee
- ❑ Pediatrics Committee